A nticholinergic medications are associated with cognitive impairment, particularly executive and memory dysfunction in late life. [1] [2] [3] [4] [5] Little is known as to whether anticholinergics are also associated with cognitive impairment in late midlife. The aim of this study was to investigate the crosssectional associations between anticholinergics and cognitive performance (ie, memory, executive function, visuospatial function, language) in persons aged 50 years and above. We also investigated the impact of APOE ε4 status. We hypothesized that regular anticholinergic use is associated with impaired performance on memory tests, particularly among APOE ε4 carriers; and impaired executive function, which may not be APOE ε4 dependent.
Measurement of Exposure to Anticholinergic Medications
Anticholinergic burden was estimated using the Anticholinergic Burden Scale (ABS; 2012). 8 Three authors (M.M.L.-S., A.H., K.R.) reviewed medications regularly taken by each participant and scored them: 0, no anticholinergics; 1, medications with possible anticholinergic effects; 2 or 3, definite anticholinergics, depending on severity of anticholinergic burden. If a participant reported taking multiple anticholinergics the scores were added. The maximum ABS in our sample was 6. We dichotomized participants into 2 groups: ABS ≥ 2 [AC+ (taking anticholinergics)] and ABS ≤ 1 [AC− (not taking anticholinergics)]. Scoring and dichotomization was reviewed by senior investigators (R.J.C., Y.E.G.).
Measurement of Cognitive Function
All participants underwent a neuropsychological test battery 9 assessing 4 cognitive domains: (1) 
Statistical Analyses
We adjusted for confounders by frequency matching the exposed (AC+) and unexposed (AC−) group by age ( ± 5 y), sex, and years of education ( ± 2 y) at 1:4 ratio. We assessed demographic differences between AC+ and AC− groups using t test and χ 2 test; and differences in neuropsychological test scores between groups (AC+ vs. AC−; AC +/APOE ε4+ vs. AC−/APOE ε4−) using t test and Wilcoxon-rank-sum test. Spearman correlations were used to examine the correlation between neuropsychological test scores and ABS. We conducted multiple regression analyses to model the relationship between neuropsychological test scores with age, ABS, and APOE ε4 status. We computed 2 statistical models: a reduced model including age and ABS, and a full model additionally including the interaction of the coefficients. The reduced model was eventually chosen as partial F tests indicated that it was as accurate as the full model. In all analyses, we primarily focused on executive function and memory; in secondary analyses we investigated visuospatial function and language. Statistical analyses were conducted using R software version R 3.3.1.
RESULTS
There were no significant differences between AC+ (N = 51) and AC− (N = 204) for age, years of education, sex, or APOE ε4 status. AC+ scored significantly lower than AC− on PASAT-2; no other differences were observed (Table 1) . There were significant correlations between ABS and few cognitive test scores: AVLT-TL (r = −0.24, P < 0.001), AVLT-LTM (r = −0.27, P < 0.001), VRT (r = −0.16, P < 0.01), and WAIS-DSS (r = −0.08, P < 0.05). AC+ performed worse in all visuospatial and most language tests, but only the difference in JLO correct score [mean (SD); 23.46 (4.1) vs. 24.69 (3.7), P = 0.026] was significant. There were no significant differences between AC+/APOE ε4+ and AC−/APOE ε4− for any cognitive test. ABS did not have a significant effect on the regression model in any memory and executive function cognitive test (Table 2) ; rather it was age that had a main effect (P < 0.05). When APOE ε4 status was included as coefficient in the regression models, it did not significantly interact with ABS on any cognitive measure.
DISCUSSION
In this cross-sectional study, we observed a significant difference between AC+ and AC− only in 1 measure of executive function. However, there was a nonsignificant trend for worse performance of AC+ as compared with AC− in 
WAIS-DSS
most memory and executive function tests. There was no consistent dose-effect relationship between ABS and test scores in any of the cognitive domains. Our findings were not impacted by APOE ε4 status. Anticholinergic burden has been associated with cognitive decline, particularly in individuals aged 70 years and above. For example, anticholinergic burden was associated with impaired memory and executive function; 3 as well as with lower cognitive scores and APOE ε4 genotype. 2 The differences between ours and other studies may be due to several reasons; for example, our sample was relatively younger; we adjusted for confounders by design and analysis making our results more conservative; we administered domain-specific cognitive tests, whereas other studies used global cognitive tests. Furthermore, investigators reported that injection of low-dose scopolamine led to impaired learning efficiency, working memory and executive function in Aβ+ participants; but no difference was observed between APOE ε4 carries and noncarriers. 10 Although their sample was similar to ours in demographics, they conducted a clinical trial and our study was observational.
One strength of our study is that we rigorously measured cognition. Second, we accounted for confounders by matching AC+ and AC− groups for age, sex, and education. Furthermore, our data are derived from large, published cohorts. ABS rating was carried out by 3 authors and revised multiple times for quality control purpose. Finally, our sample was free of potentially confounding medical or neuropsychiatric problems. A major limitation of our study is its cross-sectional design. In addition, drug use was selfreported, thus, we cannot exclude recall bias. Lastly, we conducted analyses on various tests which may raise concerns about multiple comparison bias. However, our analyses were led by a priori hypotheses derived from the existing literature which makes multiple comparison bias a less likely explanation for our findings.
In this study among persons aged 50 years and above, anticholinergics were not associated with cognitive impairment. Therefore, our study does not support the growing concern that anticholinergic medication use may be associated with cognitive impairment in late midlife. However, given our cross-sectional study design, we cannot establish a cause-effect relationship or rule out the possibility that anticholinergics may impact cognitive function in the longterm. Therefore, our results should be considered preliminary until confirmed by a prospective cohort study.
